JP2003530314A - 固体経口投薬形態 - Google Patents

固体経口投薬形態

Info

Publication number
JP2003530314A
JP2003530314A JP2001542905A JP2001542905A JP2003530314A JP 2003530314 A JP2003530314 A JP 2003530314A JP 2001542905 A JP2001542905 A JP 2001542905A JP 2001542905 A JP2001542905 A JP 2001542905A JP 2003530314 A JP2003530314 A JP 2003530314A
Authority
JP
Japan
Prior art keywords
liquid
oral dosage
dosage form
solid
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001542905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530314A5 (https=
Inventor
バーンサイド，ベス，エイ．
フランナー，ヘンリー，エイチ．
グオ，シャオディ
チャン，ロン，クン
Original Assignee
シャイア ラボラトリーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャイア ラボラトリーズ，インコーポレイテッド filed Critical シャイア ラボラトリーズ，インコーポレイテッド
Publication of JP2003530314A publication Critical patent/JP2003530314A/ja
Publication of JP2003530314A5 publication Critical patent/JP2003530314A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001542905A 1999-12-08 2000-12-06 固体経口投薬形態 Pending JP2003530314A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/457,248 US6793934B1 (en) 1999-12-08 1999-12-08 Solid oral dosage form
US09/457,248 1999-12-08
PCT/US2000/042606 WO2001041737A2 (en) 1999-12-08 2000-12-06 Solid oral dosage form

Publications (2)

Publication Number Publication Date
JP2003530314A true JP2003530314A (ja) 2003-10-14
JP2003530314A5 JP2003530314A5 (https=) 2006-06-22

Family

ID=23815987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001542905A Pending JP2003530314A (ja) 1999-12-08 2000-12-06 固体経口投薬形態

Country Status (6)

Country Link
US (1) US6793934B1 (https=)
EP (1) EP1235559A2 (https=)
JP (1) JP2003530314A (https=)
AU (1) AU4139701A (https=)
CA (1) CA2393588A1 (https=)
WO (1) WO2001041737A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508301A (ja) * 2001-07-06 2005-03-31 ライフサイクル ファーマ エー／エス 制御された凝集
JP2005530835A (ja) * 2002-06-25 2005-10-13 ニコックス エス エイ 改良された生物学的利用能を有する液体薬剤の経口医薬形態

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
CA2540225C (en) * 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US7337483B2 (en) * 2004-01-23 2008-03-04 Allen Medical Systems, Inc. Surgical positioning apparatus
US20060051409A1 (en) * 2004-09-08 2006-03-09 Groenewoud Pieter J Bezonatate liquid hard capsule dosage form
US20060222700A1 (en) * 2005-04-05 2006-10-05 Groenewoud Pieter J Tablet and capsule form of liquid active ingredient
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20080207745A1 (en) * 2007-02-24 2008-08-28 Sri International Orally-absorbed formulation for paromomycin
US8445545B2 (en) * 2008-05-07 2013-05-21 Nicholas DeSica Pharmaceutical composition, method of preparation and methods of treating aches/pains
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
CN104203238A (zh) 2011-11-10 2014-12-10 纪念斯隆-凯特琳癌症中心 用亚苄基苯甲酰肼治疗卵巢癌
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102290178B1 (ko) * 2013-03-13 2021-08-18 트리스 파마 인코포레이티드 벤조나테이트 변형 방출 고체 정제 및 캡슐
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
WO2016200345A1 (en) 2015-06-12 2016-12-15 Santa Farma İlaç Sanayi̇ A. Ş. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics.
US11938224B1 (en) 2016-04-08 2024-03-26 Tris Pharma Inc Benzonatate modified release solid tablets and capsules
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61186313A (ja) * 1985-02-12 1986-08-20 Dainippon Pharmaceut Co Ltd バルプロ酸ナトリウム製剤
JPS6281309A (ja) * 1985-10-02 1987-04-14 Kanebo Ltd バルプロ酸ナトリウム徐放錠
EP0448091A2 (en) * 1990-03-23 1991-09-25 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
EP0891776A1 (en) * 1997-07-17 1999-01-20 McNEIL-PPC, INC. Simethicone/anhydrous calcium phosphate compositions
WO1999032128A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
WO2000027393A1 (en) * 1998-11-06 2000-05-18 Fuji Chemical Industry Co., Ltd. Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same
WO2000038655A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Dosage forms comprising porous particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182103A (en) * 1985-12-09 1993-01-26 Shiseido Company, Ltd. Magnesium aluminometasilicate coated composite powder and use thereof
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
DE69942205D1 (de) 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61186313A (ja) * 1985-02-12 1986-08-20 Dainippon Pharmaceut Co Ltd バルプロ酸ナトリウム製剤
JPS6281309A (ja) * 1985-10-02 1987-04-14 Kanebo Ltd バルプロ酸ナトリウム徐放錠
EP0448091A2 (en) * 1990-03-23 1991-09-25 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
EP0891776A1 (en) * 1997-07-17 1999-01-20 McNEIL-PPC, INC. Simethicone/anhydrous calcium phosphate compositions
WO1999032128A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
WO2000027393A1 (en) * 1998-11-06 2000-05-18 Fuji Chemical Industry Co., Ltd. Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same
WO2000038655A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Dosage forms comprising porous particles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508301A (ja) * 2001-07-06 2005-03-31 ライフサイクル ファーマ エー／エス 制御された凝集
JP2005530835A (ja) * 2002-06-25 2005-10-13 ニコックス エス エイ 改良された生物学的利用能を有する液体薬剤の経口医薬形態

Also Published As

Publication number Publication date
US6793934B1 (en) 2004-09-21
CA2393588A1 (en) 2001-06-14
WO2001041737A2 (en) 2001-06-14
EP1235559A2 (en) 2002-09-04
WO2001041737A3 (en) 2002-01-03
AU4139701A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
JP2003530314A (ja) 固体経口投薬形態
JP2003530314A5 (https=)
Nazzal et al. Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters
Bolhuis et al. Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. II. The choice of super disintegrants and effect of granulation
JP4901469B2 (ja) 生物学的利用能および／または溶解度を増大させるための含浸粉末とその製造方法
JP2010509363A (ja) 固体剤形の多相医薬組成物の製造方法
US20090263479A1 (en) Formulations for poorly permeable active pharmaceutical ingredients
EP2590630B1 (en) Oral dosage form of deferasirox
JP2011516527A (ja) 医薬品有効成分の造粒
Elkadi et al. The development of self-nanoemulsifying liquisolid tablets to improve the dissolution of simvastatin
EP1855655A2 (en) Tablets with improved drug substance dispersibility
WO2019219823A1 (en) Solid dispersion containing ritonavir
EP1467713B1 (en) Tabletting process
CN112353845B (zh) 含中药挥发油的热熔挤出组合物及其制备方法和药物制剂
WO2011120530A1 (en) Porous tablets as carriers for liquid formulations
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
WO2007120838A2 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
Hasan et al. Effect of self-microemulsifying lipid formulations on the dissolution and compaction profiles of tablets containing theophylline; a BCS class I compound
CN101217942A (zh) 生物增强组合物
KR100380841B1 (ko) 데소게스트렐(desogestrel)을함유하는정제또는캡슐
TW575434B (en) A pharmaceutical mixture comprising a profen
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
EP2953617A1 (en) Pharmaceutical compositions incorporating low-dose drugs
TWI361080B (https=)
El-Setouhy et al. Effect of different meltable binders on the disintegration and dissolution behavior of zolmitriptan oromucosal fast melt tablets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100525